Healx has dosed the first subject in the open-label Phase II INSPIRE-NF1 trial to assess the efficacy and safety of HLX-1502 in individuals with neurofibromatosis type 1 (NF1), a rare genetic disorder ...

Shares of SpringWorks Therapeutics SWTX have rallied 32.9% in the past three months compared with the industry’s increase of ...

It’s the first treatment approved for both adults and children with NF1-related tumors. The FDA’s decision was based on positive results from a clinical trial involving 114 people (58 adults ...

The US Food and Drug Administration has approved mirdametinib for the treatment of neurofibromatosis type 1 (NF1) in adults and children. The drug, developed by SpringWorks Therapeutics ...

RECKGIST score may predict recurrence in neurofibromatosis type 1 GISTs, potentially guiding treatment decisions, according ...

GOMEKLI is the first FDA-approved treatment for adult and pediatric NF1-PN, showing effective tumor reduction and manageable safety. SpringWorks Therapeutics has announced the FDA approval of ...

Healx has dosed the first patient in a Phase II trial assessing its lead pipeline candidate HLX-1502 in patients with neurofibromatosis type 1 (NF1), while the FDA approved SpringWorks Therapeutics’ ...

Genetic changes alone don’t fully explain tumor growth in NF-1, pointing to other contributing factors. This insight may ...

Despite its impact, treatment options remain limited, with many patients facing invasive surgeries or therapies with severe side effects. A Potential Breakthrough for NF1 Patients “This trial ...

Researchers have found in a nonrandomised pilot trial that selumetinib showed a reduction in cutaneous neurofibromatosis ...

Gomekli is the first medication approved for both adult and pediatric patients with NF1-PN. The Food and Drug Administration (FDA) has approved Gomekli ™ (mirdametinib) for the treatment of ...

Discover a study that used the Skindex-29 assessment to evaluate emotional wellbeing during selumetinib cycles.